322
Oct 19 (Reuters) – Astellas Pharma Inc: * PFIZER: CO & ASTELLAS ANNOUNCE FINAL OVERALL SURVIVAL RESULTS FROM PHASE 3 EMBARK STUDY FOR XTANDI IN COMBINATION WITH LEUPROLIDE * PFIZER: XTANDI PLUS LEUPROLIDE REDUCED RISK OF DEATH BY 40% VERSUS LEUPROLIDE ALONE IN MEN WITH A TYPE OF ADVANCED PROSTATE CANCER Source: https://tinyurl.com/tbbct8sw Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
